{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:21:51Z","timestamp":1791328911230,"version":"4.3.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jdcjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.jdiacomp.2016.11.021","type":"journal-article","created":{"date-parts":[[2016,12,14]],"date-time":"2016-12-14T13:37:35Z","timestamp":1481722655000},"page":"758-765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"title":["A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy"],"prefix":"10.1016","volume":"31","author":[{"given":"Shigehiro","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daishiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Myoishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Nowack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kolkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2016.11.021_bb0005","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc14-S014","article-title":"Standards of medical care in diabetes \u2013 2014","volume":"37","author":"American Diabetes Association","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.jdiacomp.2016.11.021_bb0010","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.jdiacomp.2016.11.021_bb0015","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy: Results from the RENAAL study","volume":"163","author":"Bakris","year":"2003","journal-title":"Archives of Internal Medicine"},{"issue":"8","key":"10.1016\/j.jdiacomp.2016.11.021_bb0020","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jdiacomp.2016.11.021_bb0025","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.jdiacomp.2016.11.021_bb0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1016\/j.jdiacomp.2016.11.021_bb0035","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2337\/diacare.27.4.874","article-title":"Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study","volume":"27","author":"Chan","year":"2004","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jdiacomp.2016.11.021_bb0040","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.jdiacomp.2016.11.021_bb0045","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1016\/j.jdiacomp.2016.11.021_bb0050","first-page":"296","article-title":"Comparison of Jaffe rate assay and enzymatic method for the measurement of creatinine clearance","volume":"38","author":"Horio","year":"1996","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.11.021_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: Accuracy and use for population estimates","volume":"56","author":"Horio","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1016\/j.jdiacomp.2016.11.021_bb0060","first-page":"1034","article-title":"Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012","volume":"54","author":"Japan Nephrology Society","year":"2012","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.11.021_bb0065","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.11.021_bb0070","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.semnephrol.2014.04.008","article-title":"Prediction and management of hyperkalemia across the spectrum of chronic kidney disease","volume":"34","author":"Lazich","year":"2014","journal-title":"Seminars in Nephrology"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.11.021_bb0075","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2337\/dc06-1998","article-title":"Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes","volume":"30","author":"Makino","year":"2007","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.11.021_bb0080","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/1744-9987.12378","article-title":"An overview of regular dialysis treatment in Japan (as of 31 December 2013)","volume":"19","author":"Masakane","year":"2015","journal-title":"Therapeutic Apheresis and Dialysis"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.11.021_bb0085","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl. 1","key":"10.1016\/j.jdiacomp.2016.11.021_bb0090","first-page":"S79","article-title":"Nephropathy in diabetes","volume":"27","author":"Molitch","year":"2004","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.jdiacomp.2016.11.021_bb0095","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2215\/CJN.07370713","article-title":"Aldosterone breakthrough during angiotensin receptor blocker use: More questions than answers?","volume":"8","author":"Navaneethan","year":"2013","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"16","key":"10.1016\/j.jdiacomp.2016.11.021_bb0100","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"issue":"31","key":"10.1016\/j.jdiacomp.2016.11.021_bb0105","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"European Heart Journal"},{"issue":"10","key":"10.1016\/j.jdiacomp.2016.11.021_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"The New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.jdiacomp.2016.11.021_bb0115","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: A randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.jdiacomp.2016.11.021_bb0120","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1159\/000371497","article-title":"Rationale, design, and baseline characteristics of ARTS-DN: A randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy","volume":"40","author":"Ruilope","year":"2014","journal-title":"American Journal of Nephrology"},{"issue":"5","key":"10.1016\/j.jdiacomp.2016.11.021_bb0125","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circulation Journal"},{"issue":"1","key":"10.1016\/j.jdiacomp.2016.11.021_bb0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.11.021_bb0135","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","article-title":"Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy","volume":"70","author":"Schjoedt","year":"2006","journal-title":"Kidney International"},{"issue":"3","key":"10.1016\/j.jdiacomp.2016.11.021_bb0140","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1677\/joe.0.0910457","article-title":"Rise in plasma concentration of aldosterone during long-term angiotensin II suppression","volume":"91","author":"Staessen","year":"1981","journal-title":"The Journal of Endocrinology"},{"key":"10.1016\/j.jdiacomp.2016.11.021_bb0145","author":"The Japan Diabetes Society"},{"issue":"4","key":"10.1016\/j.jdiacomp.2016.11.021_bb0150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10157-013-0879-4","article-title":"Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes","volume":"18","author":"Wada","year":"2014","journal-title":"Clinical and Experimental Nephrology"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716306031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872716306031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T21:21:12Z","timestamp":1536182472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872716306031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1056872716306031"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.11.021","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727146123.793527044","asserted-by":"object"}]},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.11.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}